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INTRODUCTION
         Hypogonadism is an important reason for boys and girls attending the 
endocrinology clinic. 
        Delayed  Puberty  or  decreased  development  of  secondary  sexual 
characters has to be evaluated, if puberty is not attained by age 14 years in 
boys and age 13 years in girls, an age that is 2-2.5 standard deviations above 
the mean for healthy children.
         Delayed puberty is more common in boys than girls.
         There are four main categories of delayed puberty:
1.     Constitutional delay of growth and puberty (60% of cases),
2.     Functional hypogonadotropic hypogonadism caused by 
6
      Systemic illness or malnutrition (20% of cases),
3.     Hypogonadotropic hypogonadism caused by genetic or acquired 
      defects in the hypothalamic-pituitary regions (10% of cases),
4.     Hypergonadotropic hypogonadism secondary to primary gonadal
      failure (15% of cases).
 
             Functional hypogonodotropic hypogonadism is more common in girls 
than in boys, due to their increased susceptibility to adverse effects of energy 
imbalance resulting from dieting, exercise and or eating disorders.
             In this study, an attempt is made to identify and appropriately classify 
patients presenting with hypogonadism. Optimal therapeutic interventions 
could help in physical development and overcome emotional trauma. 
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7AIMS AND OBJECTIVES
1. To evaluate the aetiology of hypogonadism in individuals who present 
with reduced secondary sexual characters or delayed puberty.
8
2.  To find out the type of hypogonadism as either hypogonadotropic or 
hypergonadotropic and to treat them accordingly.
h
REVIEW OF LITERATURE
Hypogonadism is broadly classified into hypogonadotropic hypogonadism and 
hypergonadotropic hypogonadism. Hypogonadism can be congenital or acquired. 
Hypogonadotropic hypogonadism implies pituitary hormonal deficiency or 
hypothalamic hormone deficiency, whereas hypergonadotropic hypogonadism
9
implies primary gonadal failure and subsequent increase in the level of pituitary 
hormones.
FOLLOWING ARE THE CAUSES FOR DELAYED PUBERTY OR 
HYPOGONADISM IN BOYS (16, 18)
A. Constitutional delay of growth and puberty.
B. Systemic disorders- chronic disease, malnutrition and anorexia 
nervosa
C. Functional disorders due to excessive exercise, dieting and usage of 
Anabolic Steroids.
D. Structural causes-
Tumors- craniopharyngioma, germinoma, gliomas, meningiomas
Infiltrative disorders- like Sarcoidosis, Hemochromatosis 
 and Histiocytosis X
E. Head Trauma, Radiotherapy and surgery   
A.
A
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B. Hypothalamic-hypophyseal  causes  of  pubertal  failure  (low 
gonadotropins)
1. Congenital disorders
a. Hypothalamic syndromes like Prader-Willi syndrome.
b. Idiopathic  hypogonadotropic  hypogonadism-congenital  or 
adult onset
c. Partial  forms  of  GnRH deficiency-Fertile  Eunuch Syndrome 
and delayed puberty
d. Kallmann syndrome
e. GnRH receptor mutations
f. Adrenal hypoplasia congenita
g. PROP1 mutations
h. Other mutations affecting pituitary development/function 
2. Acquired disorders.
a. Pituitary tumors like pituitary adenoma.
b. Hyperprolactinemia
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Hypergonadotropic hypogonadism in males
       Gonadal causes of pubertal failure (Elevated Gonadotropins)
         1. Klinefelter syndrome
         2. Bilateral undescended testes or anorchia (vanishing testis syndrome 
                   Or testicular regression syndrome)( 14)
(
       3.   Orchitis
       4.   Chemotherapy or radiotherapy
       5.   Androgen insensitivity
       6.   Inactivating mutations of
             LH beta subunit
             FSH beta subunit
             LH receptor
             FSH receptor
       7.   Sertoli cell only syndrome.
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       8.   LH resistance.
       9.   Testicular biosynthetic defects.
Differential diagnosis of delayed puberty in girls is:
Hypergonadotropic hypogonadism
• Ovarian
1. Turner syndrome
2. Gonadal dysgenesis with mosaic karyotype
3.
4. Pure Gonadal dysgenesis (Swyer syndrome)
5. Chemotherapy/radiation therapy
6. Galactosemia
7. Autoimmune oophoritis
8. Congenital lipoid hyperplasia
• Steroidogenic enzyme abnormalities
1. 17 alpha-hydroxylase abnormalities
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2. Aromatase deficiency
• Gonadotropin/receptor mutations
      FSH beta, LHR, FSHR
• Androgen resistance syndrome
Hypogonadotropic hypogonadism
GENETIC
• Hypothalamic syndromes due to mutation of
Leptin/leptin receptor
HESX1 (septooptic dysplasia)
PC1 (prohormone convertase)
• Idiopathic hypogonadotropic hypogonadism and Kallmann 
Syndrome due to mutation of genes-KAL, FGFR1, GnRHR, GPR54
• Abnormalities of pituitary development/function - PROP1
CNS TUMORS/INFILTRATIVE DISORDERS
1. Craniopharyngioma(21)
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2. Astrocytoma, germinoma, glioma
3. Prolactinomas, other pituitary tumors
4. Histiocytosis X
5. Chemotherapy/radiation
FUNCTIONAL
1. Chronic diseases
2. Malnutrition
3. Excessive exercise
4. Eating disorders
Anomalies of the genital tract
• Müllerian  agenesis  (e.g.  Mayer-Rokitansky-Kuster-Hauser 
syndrome) breast present with rudimentary or absent uterus
• Congenital  or  acquired  anatomic  obstruction  (e.g.,  imperforate 
hymen, transverse vaginal septum, Asherman syndrome, endometrial 
destruction due to severe infection or surgery)
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• Androgen  insensitive  syndrome  (absent  uterus  with  normal  breast 
development)
Androgen Insensitivity Syndrome
Mutations in the androgen receptor cause resistance to androgen (testosterone, 
DHT)  action  causing  Androgen  Insensitivity  Syndrome  (AIS).  AIS  are  a 
spectrum of disorders that affect 1 in 100,000 chromosomal males. Because 
the  androgen  receptor  is  X-linked,  only  males  are  affected  and  maternal 
carriers  are  phenotypically  normal.  XY  individuals  with  complete  AIS 
(formerly testicular feminization syndrome) have a female phenotype, normal 
breast development (due to aromatization of testosterone), a short vagina but 
no  uterus  (because  Mullerian  Inhibiting  Substance  production  is  normal), 
scanty  pubic  and  axillary  hair,  and  female  psychosexual  orientation. 
Gonadotropin  levels  low,  normal  or  elevated,  depending  on  the  degree  of 
androgen resistance and the contribution of estradiol to feedback inhibition of 
the hypothalamic-pituitary gonadal axis.  Most patients present in childhood 
with  inguinal  herniae  (containing  testes)  or  with  primary  amenorrhea  in 
adulthood.  Gonadectomy  is  usually  performed,  as  there  is  a  low  risk  of 
malignancy,  and  estrogen  supplementation  is  prescribed.  Alternatively,  the 
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gonads can be left in situ until breast development is complete. The use of 
graded dilators in adolescence is usually sufficient to dilate the vagina and 
permit sexual intercourse.
Partial  AIS  (Reifenstein  syndrome) results  from  less  severe  loss  of 
Androgen  receptor  mutations.  Patients  often  present  in  infancy  with 
perineoscrotal hypospadias, small undescended testes, and with gynecomastia 
at the time of puberty. Those individuals raised as males require hypospadias 
repair  in  childhood  and  breast  reduction  in  adolescence.  Supplemental 
testosterone  rarely  enhances  androgenization  significantly,  as  endogenous 
testosterone is already increased. More severely underandrogenized patients 
present  with  clitoral  enlargement  and  labial  fusion  and  may  be  raised  as 
females.  The  surgical  and  psychosexual  management  of  these  patients  is 
complex and requires active involvement of parents and the patient during the 
appropriate stages of development.
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 HYPOGONADOTROPIC HYPOGONADISM
Secondary  hypogonadism  results  by  impaired  secretion  of  pituitary 
gonadotropins,  luteinizing  hormone  and  follicle  stimulating  hormone  is 
characterized by low testosterone or low estradiol in the setting of low LH 
(Luteinizing hormone) and low FSH (follicle-stimulating hormone).
Patients with severe deficiency of have complete absence of pubertal 
development, sexual infantilism and in some cases, causes hypospadias and 
undescended  testis  in  males.  Patients  with  partial  gonadotropin  deficiency 
have delayed or arrested sex development.
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Hypogonadotropic hypogonadism can be classified into congenital and 
acquired  disorders.  Congenital  disorders  most  commonly  involve  GnRH 
(Gondotropin  releasing  hormone),  which  leads  to  gonadotropin  deficiency. 
Acquired disorders are much more common than congenital disorders and may 
result  from  variety  of  sellar  mass  lesions  or  infiltrative  diseases  of  the 
hypothalamus or pituitary.
CONGENITAL DISORDERS ASSOCIATED WITH GONADOTROPIN 
DEFICIENCY
Most  cases of  congenital  hypogonadotropic  hypogonadism are idiopathic, 
despite extensive endocrine testing and imaging studies of the sellar region. 
Among  known  causes,  familial  hypogonadotropic  hypogonadism  can  be 
transmitted as an X-Linked (20%), autosomal recessive (30%) or autosomal 
dominant (50%) trait. 
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         Idiopathic hypogonadotropic hypogonadism and Kallmann syndrome are 
characterized by an isolated defect in GnRH secretion as evidenced by (16)
1. Complete  or  partial  absence  of  any  GnRH-induced  LH 
pulsations.
2. Normalization of pituitary and gonadal function in response to 
physiologic regimens of exogenous GnRH replacement.
3. Normal  baseline and reserve testing of  the remainder of the 
hypothalamic-pituitary axes and
4. Normal findings on radiographic imaging of the hypothalamic-
pituitary region.
Kallmann syndrome is an X-linked disorder caused by mutations in the 
KAL1 gene, which encodes anosmin, a protein that mediates the migration of 
neural  progenitors  of  the  olfactory  bulb  and  GnRH-  producing  neurons. 
These individuals have GnRH deficiency and variable combinations of 
anosmia  or  hyposmia,  renal  agenesis,  synkinesia,  cleft  lip,  cleft  palate, 
oculomotor/visuospatial  defects,  gut malrotations and mirror movements.  In 
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MRI there will be absence of anomalous morphology or absent olfactory bulbs 
which  provides  us  a  presumptive  diagnosis  of  Kallmann  syndrome. (24) 
In individuals  with Kallmann syndrome Gondatropin secretion and fertility 
can  be  restored  by  administration  of  pulsatile  GnRH  or  by  gonadotropin 
replacement. (17) 
Mutations in the FGFR1 gene cause an autosomal dominant form of 
hypogonadotropic  hypogonadism  that  resembles  Kallmann  syndrome. 
Prokineticin  2(PROK2)  also  encodes  a  protein  involved  in  migration  and 
development  of  olfactory  and  GnRH  neurons.  Recessive  mutations  in  the 
PROK2  cause  anosmia  and  hypogonadotropic  hypogonadism.  X-linked 
hypogonadotropic hypogonadism also occurs in adrenal hypoplasia congenita, 
a disorder caused by mutations in the DAX1 gene, which encodes a nuclear 
receptor in the adrenal gland and reproductive axis.
Adrenal hypoplasia congenital is characterized by absent development 
of the adult zone of adrenal cortex, leading to neonatal adrenal insufficiency. 
Puberty usually does not occur or is arrested, reflecting variable degrees of 
gonadotropin deficiency.
g
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Mutations  of  steroidogenic  factor  1  (SF1)  less  commonly  cause  sex 
reversal and hypogonadotropic reversal. GnRH receptor mutations account for 
approximately 40% of the autosomal recessive and 10% of sporadic cases of 
hypogonadotropic hypogonadism.
Recessive  mutations  in  the  G-protein-coupled  receptor  GPR54 cause 
gonadotropin  deficiency  without  anosmia.  A  number  of  homeodomain 
transcription factors are involved in the development of differentiation of the 
specialized hormone producing cells within the pituitary gland.
Mutations  in  GPR54,  a  G  protein–coupled  receptor  gene,  cause 
autosomal  recessive  idiopathic  hypogonadotropic  hypogonadism in  humans 
and mice, suggesting that this receptor is essential for normal gonadotropin-
releasing hormone physiology and for puberty. (28)
Patients  with mutations of  PROP1 have combined pituitary hormone 
deficiency that includes GH, prolactin, thyroid-stimulating hormone, LH and 
FSH,  but  not  ACTH.  LHX3 mutations  cause  combined  pituitary  hormone 
deficiency in association with cervical spine rigidity. HESX1 mutations cause 
septooptic dysplasia and combined pituitary hormone deficiency.
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There are two syndromes commonly associated with hypogonadism are 
Prader-Willi  syndrome  and  Lawrence-Moon  syndrome.  Prader-Willi 
syndrome is characterized by obesity, hypotonic musculature, mental 
retardation,  hypogonadism,  short  stature  and  small  hands  and  feet. 
Prader Willi syndrome is a genomic imprinting disorder caused by deletions of 
the proximal portion of the paternal chromosome 15q. Uniparental disomy of 
the maternal alleles or mutations of the genes/loci are involved in imprinting.
Lawrence-Moon  syndrome  is  an  autosomal  recessive  disorder 
characterized by obesity, hypogonadism, mental retardation, polydactyly and 
retinal pigmentosa. Recessive mutations of leptin, or its receptor, cause severe 
obesity  and  pubertal  arrest,  apparently  because  of  hypothalamic  GnRH 
deficiency.
ADULT ONSET IDIOPATHIC HYPOGONADOTROPIC HYPOGONADISM
In this group of patients,  puberty occurs normally, but post  pubertal, 
there is decrease in libido and fertility in the presence of testes that are of 
normal  or  near  normal  size.  Biochemically  these  patients  cannot  be 
distinguished from subjects with congenital GnRH deficiency in that they have 
a  pulsatile  pattern of  LH secretion associated  with  low serum testosterone 
levels. Recent studies have demonstrated that after a period of GnRH or hCG 
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administration in patients with IHH, reversal of hypogonadism is possible and 
those  patients  had  sustained  adult  levels  of  testosterone  even  after 
discontinuation of hormonal therapy. (17)
VARIANT OR PARTIAL FORMS OF GNRH DEFICIENCY: FERTILE 
EUNUCH SYNDROME. (16) 
           The fertile eunuch syndrome is thought to represent an incomplete form 
of  GnRH  deficiency.  In  this  disorder,  the  enfeebled  endogenous  GnRH 
secretion is sufficient to achieve the intra-testicular testosterone concentrations 
needed to support spermatogenesis and testicular growth but is insufficient to 
achieve  the systemic testosterone levels  necessary for  full  virilization.  The 
clinical presentation of fertile eunuch is similar to that of mid pubertal boys.
The  Fertile  Eunuch  Variant  of  Idiopathic  Hypogonadotropic 
Hypogonadism:  (26)  Spontaneous  Reversal  Associated  with  a  Homozygous 
Mutation  in  the  Gonadotropin-Releasing  Hormone  Receptor-1  is  achieved 
with treatment of  hCG even for few (4)months . Following cessation of hCG 
therapy,  the  patient  demonstrated  reversal  of  his  hypogonadotropism  as 
evidenced  by normal  adult  male  testosterone  levels  and the  appearance  of 
pulsatile luteinizing hormone secretion. 
TREATMENT
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          IHH men have an incomplete GnRH deficiency and that long term 
exogenous GnRH administration induces pituitary and gonadal priming, which 
subsequently enables them to sustain normal pituitary and gonadal function in 
response to their own enfeebled GnRH secretion. (25)
Human Chorionic Gonadotropin (hCG),  in the absence of exogenous 
FSH,  can  complete  spermiogenesis  in  men  with  partial  gonadotropin 
deficiency. The response to hCG in men with IHH is predicted by the initial 
testicular volume. (23)
           Although a variety of treatment regimens are used, 1500-2000 IU of 
hCG  or  recombinant  human  LH  administered  intramuscularly  three  times 
weekly is a reasonable starting dose. Testosterone levels should be measured 
6-8 weeks later and 48-72 hours after the hCG or LH   injection; HCG/rhLH 
dose  should  be  adjusted  to  achieve  testosterone  in  the  mid-normal  range. 
It may take several months for the spermatogenesis to be restored, therefore it 
is important to forewarn patients about the potential length and expense of the 
treatment  and  to  provide  conservative  estimates  of  success  rates. 
If testosterone levels are in the mid-normal range but the sperm concentrations 
are low after 6 months of therapy with hCG alone, FSH should be added. 
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A common practice is to start with the addition of 75 IU FSH three times each 
week in conjunction with hCG injections. 
           The two best predictors of success using gonadotropin therapy in 
hypogonadotropic men are testicular volume at presentation and time of onset. 
In general, men with testicular volumes > 8ml have better response rates than 
those who have testicular volumes < 4 ml.  Patients who became 
hypogonadotropic  after  puberty  experience  higher  success  rates  than  those 
who have never undergone pubertal changes. Spermatogenesis can usually be 
reinitiated by hCG alone, with high rates of success for men with post pubertal 
onset  of  hypogonadotropism.  Prior  androgen  therapy  does  not  affect 
subsequent response to gonadotropin therapy.
 
GnRH (Gonadotropin Releasing Hormone)
               In patients with documented GnRH deficiency, both pubertal 
development  and spermatogenesis  can be successfully  induced by pulsatile 
administration of low doses of GnRH. This response requires normal pituitary 
and testicular function. Therapy usually begins with an initial dose of 25ng/kg 
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per pulse  administered subcutaneously every 2 hour by a portable infusion 
pump. Testosterone, LH and FSH levels should be monitored.  
               However, most patients find intermittent gonadotropin injections 
preferable to wearing a continuous infusion pump.
ACQUIRED HYPOGONADOTROPIC DISORDERS
Severe Illness, Malnutrition and Exercise:
These  may  cause  reversible  gonadotropin  deficiency.  Although 
gonadotropin deficiency and reproductive dysfunction are well documented in 
these conditions in women, men exhibit similar but less pronounced responses. 
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The magnitude of gonadotropin suppression correlates with the severity 
of illness. The pathophysiology of reproductive dysfunction is unknown but 
likely involves combined cytokine and glucocorticoid effects.
There is a high frequency of low testosterone levels in patients with chronic 
illness such as HIV infection, end stage renal disease, chronic obstructive lung 
disease and many types of cancer and in patients receiving glucocorticoids.
Muscle  wasting  is  common  in  chronic  diseases  associated  with 
hypogonadism which also leads to debility, poor quality of life and adverse 
outcome of disease. There is a great interest in exploring strategies that can 
reverse  androgen  deficiency  or  attenuate  the  sarcopenia  associated  with 
chronic illness. Men using opioids for cancer or noncancerous pain or because 
of addiction often have suppressed testosterone and LH levels, the degree of 
suppression is dose related. Opioids suppress GnRH secretion and alter the 
sensitivity  to  feedback  inhibition  by  gonadal  steroids. 
Men  who  are  heavy  users  of  marijuana  have  decreased  testosterone 
secretion and sperm production.
OBESITY 
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         In men with mild to moderate obesity, Sex Hormone Binding Globulin 
(SHBG) levels decrease in proportions to the degree of obesity, resulting in 
lower  total  testosterone  levels.  However,  free  testosterone  levels  usually 
remain within the normal range. The decrease in SHBG levels is caused by 
increased  circulating  insulin,  which  inhibits  SHBG  production.  Estradiol 
levels  are  higher  in  obese  men  compared  to  healthy,  non  obese  controls, 
because of aromatization of testosterone to estradiol in adipose tissue. Weight 
loss is associated with reversal of these abnormalities including an increase in 
total and free testosterone levels and a decrease in estradiol levels. 
HYPERPROLACTINEMIA
Elevated  levels  of  prolactin  are  associated  with  hypogonodatropic 
hypogonadism. Prolactin inhibits hypothalamic GnRH secretion either directly 
or  through  modulation  of  tuberoinfundibular  dopaminergic  pathways.  A 
prolactin secreting tumor may also destroy the surrounding gonadotropes by 
invasion  or  compression  of  the  pituitary  stalk.  Treatment  with  dopamine 
agonists reverses gonadotropin deficiency.
SELLAR MASS LESIONS
29
           Tumors in the CNS can compress the portal vessels and impede the 
flow  of  GnRH  from  the  hypothalamus  to  the  pituitary  gland.  Pituitary 
adenomas,  craniopharyngiomas,  and  meningiomas  are  examples  of  slow-
growing nonmetastatic tumors that are uncommon causes of hypogonadotropic 
hypogonadism. Anterior pituitary prolactinomas releasing prolactin hormone 
are  the  most  common  pituitary  tumors  to  cause  hypogonadotropic 
hypogonadism.
         Other acquired disorders can disrupt pituitary function by destructive 
means, such as ischemia, infiltration, and obstruction. Head trauma, cranial 
aneurysms, and infiltrative processes (e.g., sarcoidosis, syphilis, tuberculomas) 
are examples of conditions that can disrupt pituitary function.
Pituitary adenomas that extend into the supra-sellar region can impair 
GnRH secretion and mildly increase prolactin usually less than 50 micro-liters 
because of  the impaired tonic  inhibition by  dopaminergic  pathways.  These 
tumors  should  be  distinguished  from  prolactinomas  which  secrete  higher 
levels of prolactin. The presence of diabetes insipidus suggests the possibility 
of a craniopharyngioma, infiltrative disorder, or other hypothalamic lesions.
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 HEMOCHROMATOSIS
           Hemochromatosis is a common inherited disorder of iron metabolism in 
which  an  inappropriate  increase  in  intestinal  iron  absorption  results  in 
deposition of excessive amounts of iron in parenchymal cells with eventual 
tissue damage and impaired organ function. 
Both pituitary and testis can be affected by excessive iron deposition. 
However,  the  pituitary  is  the  predominant  lesion  in  most  patients  with 
hemochromatosis  and hypogonadism.  The diagnosis  of  hemochromatosis  is 
suggested  by  the  association  of  characteristic  skin  discolouration,  hepatic 
enlargement  or  dysfunction,  diabetes  mellitus,  arthritis,  cardiac  conduction 
defects and hypogonadism.
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 PRIMARY GONADAL FAILURE
PRIMARY TESTICULAR CAUSES OF HYPOGONADISM
Common causes of  primary testicular  dysfunction include Klinefelter 
syndrome, uncorrected cryptorchidism, and cancer, chemo therapy radiation to 
the  testis,  trauma,  torsion,  infectious  orchitis,  HIV  infection,  anorchia 
syndrome  and  myotonic  dystrophy.  Primary  testicular  disorders  may  be 
associated with impaired spermatogenesis, decreased androgen production, or 
both.
CONGENITAL CAUSES:
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Klinefelter Syndrome:
         Klinefelter  Syndrome is  the most  common chromosomal  disorder 
associated with testicular dysfunction and male infertility. It occurs once in 
1000  live-born  males.  Azoospermia  is  the  rule  in  men  with  Klinefelter 
syndrome who have the 47XXY karyotype;  however,  men with mosaicism 
may have germ cells, especially at a younger age. Testicular histology shows 
hyalinization of seminiferous tubules and absence of spermatogenesis. 
h
Although their function is impaired, the number of Leydig cells appears 
to increase.  Testosterone is decreased and estradiol  is  increased,  leading to 
clinical features of undervirilization and gynecomastia. Men with Klinefelter 
syndrome are at increased risk of breast cancer, non-Hodgkin’s lymphoma and 
lung cancer and reduced risk of prostate cancer. Periodic mammography for 
breast  cancer  surveillance  is  recommended  for  men  with  Klinefelter 
Syndrome.
Cryptorchidism
Cryptorchidism occurs when there is incomplete descent of the testis 
from the abdominal cavity into the scrotum. About 30% of premature male 
infants  have  at  least  one  cryptorchid  testis  at  birth,  but  descent  is  usually 
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complete by the first few weeks of life. The incidence of cryptorchidism is 
<1% by 9 months of age. Crytorchidism is associated with increased risk of 
malignancy  and  infertility.  Unilateral  cryptorchidism,  even  when  corrected 
before puberty, is associated with decreased sperm count, possibly reflecting 
unrecognized damage to the fully descended testis  or other genetic factors. 
Epidemiologic,  clinical  and  molecular  evidence  supports  the  idea  that 
cryptorchidism, hypospadias, impaired spermatogenesis, and testicular cancer 
may be causally related to common genetic and environment perturbations and 
are components of the testicular dysgenesis syndrome.
a
VANISHING TESTIS SYNDROME- BILATERAL ANORCHIA
         The vanishing or regressed testis is an entity well known to urologists 
and  pediatric  surgeons,  affecting  approximately  5%  of  patients  with 
cryptorchidism. 
          “Vanishing testis syndrome” otherwise called as bilateral anorchia or 
“testicular  regression  syndrome”  or  46  XY  gonadal  dysgenesis is 
characterized  by  the  absence  of  testis  in  a  46XY  individual  with  a  male 
phenotype and is an important  and a well  known cause of  bilateral  absent 
testis.
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          Non-palpable testicles may be due to the vanishing testis syndrome, 
intra-abdominal position, examination obscured by obesity or scar tissue and 
rarely testicular agenesis. Laparoscopy is an excellent means of distinguishing 
these entities without the need for open abdominal exploration. (9)
The  etiology  is  unknown;  however,  the  familial  occurrence  of  the 
disease and the association of this phenotype with 46XY gonadal dysgenesis 
have led to the suggestion that genetic factors, which play a role in testicular 
determination,  may be involved.  Alternatively,  exploratory laparoscopy has 
suggested  that  anorchia  may  be  caused  by  a  prenatal  testicular  vascular 
accident associated with torsion during testicular descent. (14)
(
Heterozygous  partial  loss  of  function  mutations  in  SF1  may  be 
associated  with  bilateral  anorchia  (‘vanishing  testis  syndrome’)  and 
micropenis in humans. (27) 
These patients can acquire secondary sexual characters by testosterone 
supplementation but cannot procreate due to lack of gonadal tissue.
ACQUIRED TESTICULAR DEFECTS:
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Viral orchitis may be caused by mumps virus, echovirus, lymphocytic 
choriomeningitis virus, and group B arboviruses. Orchitis occurs in as many as 
one-fourth of adult men with mumps; the orchitis is unilateral in about two-
thirds and bilateral in the remainder. Orchitis usually develops a few days after 
the onset of parotitis but may precede it. The testis may return to its normal 
size and function or may undergo atrophy. Semen analysis returns to normal 
for three-fourths of men with unilateral involvement but normal for only one-
third of men with bilateral orchitis. Trauma, including testicular torsion, can 
also cause secondary atrophy of the testes. The exposed position of the testes 
in the scrotum renders them susceptible to both thermal and physical trauma, 
particularly in men with hazardous occupation.
p
Radiation and chemotherapy:
The  testes  are  sensitive  to  radiation  damage.  Doses  >200  mGy  are 
associated  with  increased  FSH  and  LH  levels  and  damage  to  the 
spermatogonia. After 800 mGy, oligospermia or azoospermia develops, and 
higher doses may obliterate the germinal epithelium. Most boys given direct 
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testicular  radiation  therapy  for  acute  lymphoblastic  leukemia  have 
permanently low testosterone levels. 
Drugs  interfere  with  testicular  function  by  several  mechanisms, 
including inhibition of testosterone synthesis (e.g. ketoconazole), blockade of 
androgen  action  (eg.spironolactone),  increased  estrogen  (eg.marijuana),  or 
direct  inhibition  of  spermatogenesis  (e.g.chemotherapy).Combination 
chemotherapy for acute leukemia, Hodgkin’s disease, and testicular and other 
cancers impair Leydig cell function and cause infertility. Cyclophosphamide 
and  combination  regions  containing  procarbazine  are  particularly  toxic  to 
germ cells. Newer regimens like ABVD (Adriamycin, bleomycin, vinblastine, 
dacarbazine) are less toxic to germ cells.
Alcohol when  consumed  in  excess  for  prolonged  periods,  decreases 
testosterone, independent of liver disease or malnutrition. Elevated estradiol 
and decreased testosterone levels may occur in men taking digitalis. Testicular 
failure also occurs as a part of polyglandular autoimmune insufficiency. 
Systemic  disease  can  cause  primary  testis  dysfunction in  addition to 
suppressing gonadotropin production. In cirrhosis, a combined testicular and 
pituitary abnormality leads to decreased testosterone production independent 
of  toxic  effects  of  ethanol.  Impaired  hepatic  extraction  of  adrenal 
37
androstenedione leads to extraglandular conversion to estrone and estradiol, 
which partially suppresses LH. Testicular atrophy and gynecomastia is present 
in one half of men with cirrhosis.
In  chronic  renal  failure,  androgen  synthesis  and  sperm production 
decrease  despite  elevated  gonadotropins.  About  one  fourth  of  men  with 
chronic renal failure have hyperprolactinemia.  Sperm density can decrease 
temporarily after acute febrile illness in absence of a change in testosterone 
production. Infertility in men with celiac disease is associated with a hormonal 
pattern typical of androgen resistance, namely elevated testosterone and LH 
levels.
Neurological  diseases associated  with  altered  testicular  function 
include myotonic dystrophy, spinobulbar muscular atrophy and paraplegia. In 
myotonic dystrophy, small testes may be associated with impairment of both 
spermatogenesis  and  Leydig  cell  function.   Spinobulbar  muscular  atrophy 
(also known as Kennedy disease) is X-linked and is caused by an expansion of 
the glutamine repeat sequences in the amino-terminal region of the AR 
(androgen  receptor).  These  patients  may  show  evidence  of  partial 
androgen insensitivity in adolescence or adulthood. Spinal cord lesions that 
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cause paraplegia can lead to a temporary decrease in testosterone levels and 
may cause persistent defects in spermatogenesis.
TREATMENT 
Testosterone replacement improves libido and overall  sexual activity; 
increases energy, lean muscle mass and bone density and gives the patient a 
better sense of well-being. 
        Injectable forms of testosterone, testosterone enanthate or cypionate are 
commonly used. Within 24 hours of administration of 200 mg testosterone 
levels  will  rise  to  supraphysiologic  levels  and  then  decline  slowly  over  2 
weeks. Testosterone levels should be about 350-600 ng /dl after 1 week of 
administration.
           Two long acting  esters,  testosterone  buciclate  and testosterone 
undeconate,  when  injected  intramuscularly,  can  maintain  circulating 
testosterone concentrations in the male range for 7-12 weeks.  
         Transdermal patches of testosterone are also available. 5mg patch a 
day is able to achieve targeted testosterone levels. 4-6 hours after application 
testosterone levels should be in mid normal range of 500-700ng/dl.
t
39
          Testosterone gels like Androgel and Testim, are available in 2.5 and 
5gram unit doses that nominally deliver 25 and 50 mg of testosterone to the 
application site. Gels have found to maintain free and total testosterone in the 
mid-normal range.
              A buccal adhesive testosterone tablet, which adheres to the buccal 
mucosa and releases testosterone as it is slowly dissolved, has been approved. 
After twice daily application of 30mg tablets,  serum testosterone levels are 
maintained within the normal male range in a majority of  treated hypogonadal 
men.
              After oral administration testosterone is well absorbed but quickly 
degrades during the first pass through the liver. 17 alpha-alkylated derivatives 
of  testosterone  are  relatively  resistant  to  hepatic  degradation  and  can  be 
administered  orally;  however,  because  of  the  potential  for  hepatotoxicity, 
including  cholestatic  jaundice,  peliosis,  and  hepatoma,  these  formulations 
should not be used for testosterone replacement.
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 HYPERGONADOTROPIC HYPOGONADISM IN FEMALES
PRIMARY OVARIAN FAILURE
The  most  common  example  of  hypergonadotropic  hypogonadism 
(i.e.  with  elevated  FSH  and  LH)  and  low  estradiol  is  found  in  Turner 
syndrome.  Between  25%  and  40%  delayed  puberty  in  girls  is  of  ovarian 
origin, with Turner syndrome constituting a majority of such patients.  Any 
patient with short stature with webbed neck, cubitus valgus, widely spaced 
nipples  with  near  normal  intelligence  with  primary  infertility  should  be 
evaluated  for  Turner’s  syndrome with ultra  sonogram of  the abdomen and 
pelvis  to  look  for  hypoplastic  uterus  and  streak/absent  ovaries  and  with 
karyotyping  to  establish  the  chromosomal  defect  of  45XO.  Patients  with 
variants  of  Turner’s  syndrome  with  mosaic  pattern  of  chromosomal 
abnormality 45XO/46XX can have near normal uterus and ovaries and they 
can have normal menstrual cycles and reproductive function.
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Gonadal dysgenesis fits the same pattern of high FSH and LH and low 
estradiol  (E2)  levels.  Gonadal  dysgenesis  is  caused by a  mosaic  karyotype 
with an abnormal X chromosome or with a normal karyotype (46, XX) and 
streak ovaries. 
s
Individuals with Perrault syndrome have gonadal dysgenesis, a normal 
karyotype,  and neuro-sensory deafness.  Swyer syndrome is illustrated by a 
phenotypically  immature  female  with  a  46  XY  karyotype  without 
testis-determining  factor  on  the  Y  chromosome.  Another  rare  cause  of 
hypergonadotropic hypogonadism is gonadotropin-resistant ovary syndrome, 
which is characterized by FSH-resistant ovaries.
Acquired causes of hypergonadotropic hypogonadism can result from 
high-dose  alkylating  chemotherapy  and  radiation  treatments  to  the  pelvis. 
Elevated  ESR  and  anti-ovarian  antibody  levels  may  suggest  autoimmune 
oophoritis,  but  such  tests  are  rarely  needed.  Autoimmune  oophoritis  is  an 
exclusionary diagnosis. 
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4HYPOGONADOTROPIC HYPOGONADISM IN FEMALES
Hypogonadotropic hypogonadism occurs when FSH and LH levels are 
low.  Hypogonadotropic  hypogonadism  may  present  prior  to  or  after  the 
completion  of  puberty.  The  most  common  causes  of  hypogonadotropic 
hypogonadism include chronic illness, starvation, excessive exercise, anorexia 
nervosa,  depression,  stress,  and  marijuana  use.  Hypogonadotropic 
hypogonadism  involves  slowed  GnRH  release  caused  by  multi-factorial 
components of decreased body fat and increased beta endorphins.
Chronic illness can affect pubertal development adversely by interfering 
with  metabolism  through  mal-absorption  and  poor  nutrition  (e.g.  Crohn 
disease,  diabetes  mellitus,  hypothyroidism  and  hyperthyroidism,  cystic 
fibrosis, anorexia nervosa, excessive exercise).
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Tumors in the CNS can compress the portal vessels and impede the flow 
of GnRH from the hypothalamus to the pituitary gland. Pituitary adenomas, 
craniopharyngiomas,  and  meningiomas  are  examples  of  slow-growing 
nonmetastatic  tumors  that  are  uncommon  causes  of  hypogonadotropic 
hypogonadism. Anterior pituitary prolactinomas releasing prolactin hormone 
are  the  most  common  pituitary  tumors  to  cause  hypogonadotropic 
hypogonadism.
h
Other acquired disorders can disrupt pituitary function by destructive 
means, such as ischemia, infiltration, and obstruction. Head trauma, cranial 
aneurysms,  and  infiltrative  processes  (e.g.,  sarcoidosis,  syphilis,  and 
tuberculomas) are examples of conditions that can disrupt pituitary function.
Abnormal  development  of  the  hypothalamus  can  result  in 
hypogonadotropic  hypogonadism.  Kallmann  syndrome  manifests  with 
anosmia, pubertal delay, and a normal response to exogenous gonadotropins. 
Kallmann  syndrome  occurs  during  embryonic  development  when  GnRH 
secreting  neurons  fail  to  migration  from  the  olfactory  area  to  the 
hypothalamus. The gene KAL1 codes for the protein associated with normal 
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migration. Other syndromes associated with hypothalamic dysfunction include 
Prader-Willi syndrome and Laurence-Moon-Biedl syndrome.
TREATMENT
            In Turner’s syndrome, Conjugated estrogen supplementation, followed 
by  progesterone  administration  to  prevent  uterine  cancer  helps  these  girls 
achieve secondary sexual characters.  
            Turner’s syndrome is a condition where recombinant Growth Hormone 
can  be  used  to  increase  the  height  of  these  girls,  other  than  in  Growth 
Hormone deficiency. (29)   
(
             In girls with idiopathic hypogonadotropic hypogonadism recombinant 
FSH  and  recombinant  HCG  administration  is  highly  useful  for  ovulation 
induction and restoring fertility. 
             Pulsatile GnRH therapy is highly effective for restoring ovulation in 
patients with hypothalamic amenorrhea.
             In patients with prolactinomas, either bromocriptine administration or 
transphenoidal hypophysectomy restores pituitary function.
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DEGREES OF CONSANGUINITY
             Genetically the degree of consanguinity of siblings is the same as that 
between a parent and child, and both are termed consanguineous in the first 
degree. An aunt or uncle shares with a niece or nephew about half the chance 
of common inheritance of a pair of siblings; thus, aunts and uncles may be 
termed consanguineous kin of the second degree. Following this logic, first 
cousins  who have  one-eighth  of  their  genes  in  common are  referred  to  as 
consanguineous  kin  of  the  third  degree.  First  half  cousins  who  have  one-
sixteenth of their genes in common are referred to as consanguineous kin of 
the fourth degree.
MATERIALS AND METHODS
SETTING
         The study was conducted on the out patients attending the Institute of 
Internal  Medicine  and  Department  of  Medical  Endocrinology,  Madras 
Medical College and Government General Hospital, Chennai.
COLLABORATION DEPARTMENTS
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          Institute of Internal Medicine.
          Department of Medical Endocrinology. 
ETHICAL COMMITTEE APPROVAL
         Institute Ethical Committee approved the study
STUDY DESIGN
        Single Center
        Non- randomized cross sectional study
 STUDY PERIOD
            Study was conducted from January 2008 to September 2008 over a 
period of   9 months
SAMPLE SIZE
           In the study period of 9 months, after applying inclusion and exclusion 
criteria, 50 patients were included.
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SELECTION OF STUDY SUBJECTS
INCLUSION CRITERIA:
1. Age- above 12 years.
2. Sex- both genders
3. Patients with underdeveloped secondary sexual characters.
4. Patients with delayed puberty.
5. Patients with primary amenorrhea in girls.
EXCLUSION CRITERIA:
1. Patients with chronic systemic illness 
2. Individuals who abuse drugs or alcohol.
3. Patients who have undergone cancer chemotherapy or radiotherapy. 
CONSENT
        All participants gave written informed consent.
METHODOLOGY.
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        Detailed  history  of  the  patients  using  a  proforma  was  taken  and 
anthropometric measurements like height, weight and arm span were noted. 
A  thorough  general  and  systemic  examination  was  done  to  rule  out  any 
systemic  illness.  Secondary  sexual  characters  were  assessed  using  Tanner 
Staging. 
        Estimation of hormonal levels was done for all patients in the study. 
Follicle stimulating hormone, luteinizing hormone, thyroid hormone, cortisol, 
growth  hormone  levels,  prolactin,  testosterone  and  estradiol  levels  were 
assessed.
         Radiological assessment including  X-ray Cone View Sella, X-ray left 
forearm and X-ray left wrist was done to asses the bone age and epiphyseal 
fusion. MRI Brain (Sella) was taken in selected patients to rule out structural 
causes of pituitary dysfunction. 
        Karyotyping was also done in certain patients to establish their genotype. 
Finally, after finding out the etiology of hypogonadism they were started on 
appropriate treatment.    
NORMAL VALUES FOR HORMONES                    
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FOLLICLE STIMULATING HORMONE 
Technology  used:   Fully  automated  bidirectionally  interfaced 
Chemiluminescent Immuno Assay.
Females                                                             
Normally Menstruating;   (mIU/ml)                
Follicular phase:  2.5-10.2
Midcycle peak:     3.4-33.4
Luteal phase:         0.5-16.9
Pregnant:               <0.3  
Post menopausal:   23.0-116.3
Males
13-70 years:  1.4-18.1(mIU/ml)
LUTENIZING HORMONE – LH (mIU/ml)
Females- normally menstruating:
Follicular phase:   1.9-12.5
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Midcycle peak:      8.7-76.3
Luteal phase:         0.5-16.9
Pregnant:               0.1-6.0
Post menopausal: 15.9-54.0
Children:               0.1-6.0
Males:         
20-70 years:         1.5-9.3
>70 years:            3.1-34.6
Free testosterone: 
Adult males:      8.9-42.50 pg/ml (pico-gram per ml)
Adult females:  0.02-3.09 pg/ml
KIT used- Biosource, Belgium. Technology used- Radio immune assay.
Total testosterone: in ng/dl (nanograms per dl)
Technology used: fully automated bidirectionally interfaced 
Chemiluminescent Immuno Assay.
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Age                                   males                                females 
1-10 years                         2-30 1-20
9.8-14.5 years       5-70 5-30
10.7-15.4years                 15-280           10-30
11.8-16.2 years               105-545           15-40
12.8-20 years      280-1100           15-70
20-50 years          241-827              -
Ovulating - 14-76
ESTRADIOL/ESTROGEN (E2)
UNITS:  pg/ml (pico-gram per ml)
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Technology used: CLIA- Chemiluminescent Immuno Assay.
Adult female:
Ovulatory cycle (by day in cycle relative to LH peak)
Follicular phase (-12 to -4 days)                 : 18.90-246.7
Mid cycle (-3 to +2 days)                            : 35.5-570.8
Luteal phase (+4 to 12 days)                       : 22.4-256.0
Untreated menopausal                                 : <44.5
Adult males                                                  : 11.60-41.20
THYROID FUNCTION TESTS:
FREE T4 (THYROXINE)                          : 0.70-1.80 ng/dl (nanograms/dl)
Technology used: competitive chemiLuminescent Immuno Assay
Total T4                                                      : 4.5-12.0 microgram/dl
Technology used: competitive chemiLuminescent Immuno Assay
Total T3                                                      : 60-200 ng/dl
Technology used: competitive chemiLuminescent Immuno Assay
 TSH                                                            : 0.3 -5.5 microIU/ml
Technology used: ultra sensitive sandwich Chemiluminescent Immuno Assay
T
CORTISOL (mcg/dl) microgram per dl
AT 8 AM: 5- 25
53
AT 4 PM: 2.5-12.5
Post dexamethasone: below basal level
Post A.C.T.H: Three to five times the basal level
GROWTH HORMONE
ADULTS
BASAL:    0.06-5.0 ng/ml (nanograms per ml)
Post Clonidine stimulation: > 10 ng/ml
Technology used: Chemi Luminescent Immuno Assay
PROLACTIN (ng/ml) nanograms per ml
Males: 2.1-17.7 
Females: 
Normally menstruating-2.8-29.2
Pregnant: 9.7-208.5
Post menopausal: 1.8-20.3    
Technology used: Chemi Luminescent Immuno Assay.    
T
STATISTICAL ANALYSIS
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SPSS 13 and Excel were used for statistical analysis
LIMITATIONS
Small number of study subjects especially females
All investigations are not done for every patient.
CONFLICT OF INTEREST
None
                                                 
55
‚56
RESULTS AND OBSERVATIONS
STUDY POPULATION CHARACTERISTICS
          Among the 50 patients included in our study 44 patients were males 
accounting for 88% of the total. The remaining 12% of patients were females.
         According to age, patients who present below 18 years of age were 39 
(78%) and above 18 years were 11(22%).  
  TABLE 1: STUDY POPULATION CHARACTERISTICS
AGE TOTAL NO OF 
PATIENTS
% MALE
S
FEMAL
ES
<18 
years
(12-18yr
s)
39
7
8
35 4
>18 
years 11
2
2
6 5
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5TABLE 2: SEX DISTRIBUTION OF STUDY POPULATION
SEX HYPOGONADOTROPIC 
HYPOGONADISM
HYPERGONADOTROPIC 
HYPOGONADISM
MALES 39 5
FEMALES 2 4
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In our study, males were predominant with 44 in number, with females only 6 
in number. Among males, 39 had hypogonadotropic hypogonadism and 5 had 
hypergonadotropic hypogonadism.
In females, 2 of them had hypogonadotropic hypogonadism and 4 of them had 
hypergonadotropic hypogonadism.
h
TABLE 3: ETIOLOGY WISE DISTRIBUTION OF 
HYPOGONADOTROPIC HYPOGONADISM
HYPOGONADOTROPIC HYPOGONADISM NO: OF 
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PATIENTS
IDIOPATHIC 33
KALLMANN SYNDROME 1
VANISHING TESTIS SYNDROME 1
HYPOPITUITARISM 4
GIGANTISM AND HYPOGONADISM 1
CRANIOPHARYNGIOMA 1
TOTAL 41
In our study, a total of 41 patients had hypogonadotropic hypogonadism. Most 
common etiology was idiopathic hypogonadotropic hypogonadism which is a 
diagnosis of exclusion.
We found out a patient with bilateral anorchia or vanishing testis syndrome, 
one patient  had kallmann syndrome, four of  them had hypopituitarism and 
interestingly one patient had features of gigantism and hypogonadism.
i
TABLE 4: ETIOLOGY WISE DISTRIBUTION OF 
HYPERGONADOTROPIC HYPOGONADISM
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HYPERGONADOTROPIC 
HYPOGONADISM
NO: OF PATIENTS
KLINEFELTER SYNDROME 5
TURNER’S SYNDROME 4
TOTAL 9
                                                       In our study, we had 9 patients with 
hypergonadotropic hypogonadism. Among them 5 had Klinefelter syndrome 
and 4 had Turner’s syndrome.
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 TABLE 5: CORRELATION BETWEEN DEGREE OF 
CONSANGUINITY AND PREVALANCE OF HYPOGONADISM
 DEGREE OF CONSANGUINITY NO: OF PATIENTS
NON-CONSANGUINOUS 30
SECOND DEGREE 12
THIRD DEGREE 7
FOURTH DEGREE 1
                                              P value <0.001(highly significant)
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In our study, we had a significant negative correlation between consanguinity 
and occurrence of hypogonadism in children. 
a
TABLE 6: CORRELATION BETWEEN BIRTH ORDER AND 
HYPOGONADISM
CORRELATION BETWEEN BIRTH ORDER AND 
HYPOGONADISM
63
FIRST 21
SECOND 16
THIRD 7
FOURTH 5
FIFTH 1
                                      P value <0.001(highly significant)
In our study, we had a significant positive correlation between birth order and 
the incidence of hypogonadism. 
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łTABLE 7: COMPARISON BETWEEN STUDY VARIABLES IN 
MALES
STUDY 
VARIABLES
     IN MALES
HYPOGONADISM
HYPOG HYPERG
COUNT MEAN SD COUNT MEAN SD
P 
VALUE
ARM SPAN 39 158.62 16.43 5 178.6 6.54 0.01
HEIGHT 39 154.51 13.1 5 168.8 3.96 0.02
WEIGHT 39 51.8 14.98 5 65.4 10.7 0.05
AS-HT 39 4.1 9.93 5 9.8 7.6 0.22
US/LS 39 0.89 0.07 5 0.9 0.04 0.70
FSH 39 1.61 1.28 5 31.6 23.8 0.001
LH 25 0.78 0.95 5 16 10.2 0.001
TOTAL 
TESTOSTERONE
39 24.98 24.62 5 61.0 70.1 0.22
                                   P Value 0 to 0.1- significant
                                   P Value 0.011 to 0.05-highly significant
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8          TABLE No. 8 CORRELATION CO-EFFICIENT OF HORMONES 
AND OTHER VARIABLES - [MALES]
VARIABLES
FSH LH TESTO
STERONE
ESTRADIOL
ARM 
SPAN WEIGHT
FSH
1.00
  44
P =.
0.90
  30
P=.000
0.21
  44
P=0.158
0.98
   8
P=0.000
0.23
  44
P=0.126
0.34
  44
P=0.023
LH
0.90
30
P=0.00
1.00
30
P=.
0.48
30
P=0.006
0.97
6
P=0.11
0.29
30
P=011
0.39
30
P=0.033
TESTOSTERONE
0.21
44
P=0.158
0.48
30
P=0.006
1.00
44
P=.
0.72
8
P=0.041
0.16
44
P=0.28
0.04
44
P=0.769
ESTRADIOL
0.98
8
0.97
6
0.72
8
1.00
8
0.5264
8
0.74
8
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P=0.000 P=0.001 P=0.041 P=. P=0.180 P=0.035
ARM SPAN
0.23
44
P=0.126
0.29
30
P=0.110
0.16
44
P=0.283
0.52
8
P=0.180
1.00
44
P=.
0.35
44
P=0.019
WEIGHT
0.34
44
P=0.023
0.39
30
P=0.33
0.045
44
P=0.769
0.74
8
P=0.035
0.35
44
P=0.019
1.00
44
P=0.002
HEIGHT 0.29
44
P=0.050
0.34
30
P=0.058
0.11
44
P=0.442
0.57
8
P=0.135
0.81
44
P=0.000
0.45
44
P=0.002
   ‘.’ IS DENOTED IN CASES WHERE CO-EFFICIENT COULD NOT BE COMPUTED
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In males, among the variables studied Arm span, height and weight and FSH 
and  LH  varied  significantly  between  hypogonadotropic  and 
hypergonadotropic hypogonadism. 
In  Males,  using  correlation  coefficients,  significant  correlation  was  found 
between FSH, LH, estradiol and weight. 
LH had positive correlation with total testosterone, estradiol and weight. 
Total testosterone correlated significantly with LH and estradiol.
Estradiol had positive correlation with FSH, LH and Total Testosterone.
Arm span had significant correlation with weight 
Height had significant correlation with FSH, LH, Armspan and weight.
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łTABLE 9: COMPARISON BETWEEN STUDY VARIABLES IN FEMALES
STUDY 
VARIABLES 
IN 
FEMALES
HYPOGONADISM
HYPOG HYPERG
P 
VALUE
COUN
T M E A N SD C O U N T M E A N SD
ARM SPAN 2 129 4.24 4 143.75 17.0 0.317
HEIGHT 2 126 0.00 4 138.50 16.9 0.38
WEIGHT 2 22.50 3.54 4 35.25 3.69 0.16
AS-HT 2 3.00 4.24 4 5.25 2.22 0.41
US/LS 2 0.90 0.00 4 0.94 0.04 0.32
FSH 2 2.11 0.19 4 95.29 65.75 0.13
ESTRA-
DIOL
2 4.15 4.74 4 13.25 1.32 0.16
                                   
                                    P Value 0 to 0.1- significant
                                   P Value 0.011 to 0.05-highly significant
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TABLE No.10 CORRELATION CO-EFFICIENT OF HORMONES 
AND OTHER VARIABLES
[FEMALES]
VARIABLES FSH LH ESTRADIOL ARM 
SPAN
WEIGHT
FSH
1.00
6
P=.
0.99
3
P=0.021
0.71
6
P=0.109
0.01
6
P=0.446
0.47
6
P=0.338
LH
0.99
3
P=.021
1.00
3
P=.
0.76
3
P=0.446
0.97
3
P=0.145
0.95
3
P=0.187
ESTRADIOL
0.71
6
P=.109
0.76
3
P=0.446
1.00
6
P=.
0.50
6
P=0.310
0.86
6
P=115
ARM SPAN
-0.01
6
P=.984
0.97
3
P=0.145
0.50
6
P=0.310
1.00
6
P=.
0.70
6
P=.143
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WEIGHT
0.47
6
P=0.338
0.95
3
P=0.187
0.86
6
P=0.27
0.70
6
P=0.115
1.00
6
P=.
HEIGHT
-0.08
6
P=0.872
0.99
3
P=0.032
0.38
6
P=0.446
0.98
6
P=0.000
0.6731
6
P=0.143
‘.’ is denoted in cases where co-efficient could not be computed
In females, significant positive correlation existed between LH and FSH, 
Weight and Estradiol, Height and LH, and Height and Arm span.
FIGURE 1:
SEX WISE DISTRIBUTION OF STUDY POPULATION
FIGURE: 2 AETIOLOGY WISE DISTRIBUTION OF 
HYPOGONADOTROPIC HYPOGONADISM                       
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FIGURE: 3 AETIOLOGY WISE DISTRIBUTION 
HYPERGONADOTROPIC HYPOGONADISM
FIGURE 4: PREVELANCE OF GYNECOMASTIA IN 
HYPOGONADISM MALES         
FIGURE 5: CORRELATION BETWEEN CONSANGUINITY IN 
PARENTS AND HYPOGONADISM      
FIGURE 6: CORRELATION BETWEEN BIRTH ORDER AND 
HYPOGONADISM
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  Individuals who present with hypogonadism can be classified either 
into hypogonadotropic or hypergonadotropic based on the pituitary hormones 
and the gonadal hormones.
        Most of the individuals in this study presented to us on just entering 
into adolescence in the age group of 12-15 years, majority below 18 years.
       Although most of the individuals with IHH present in adolescence, few 
of them present in adult age group.  In this study we had 5 patients presenting 
above  the  age  of  18  years  with  IHH.  Similar  observation  was  found  by 
Nachtigall et al.  (36) 
In  this  study,  most  of  them  who  presented  with  hypergonadotropic 
hypogonadism, presented above 18 years (5 out of 9).           
In this study we had a major proportion of males who presented with 
hypogonadism than females which may be due cultural practices prevailing in 
rural areas. 
Among  hypogonodotropic  hypogonadism,  in  our  study,  we  had 
Idiopathic hypogonadotropic hypogonadism (IHH) as the most common cause 
and most of them were males. This  correlated well with the study earlier done 
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by Seminara et al 1998 who showed a male-to-female ratio of nearly 4:1 
[Seminara et al 1998] (31). But in this study we had a very high ratio of 15.5:1 
due to small number of females.
The probability of a man being infertile increased as mother's age at 
birth  increased  (regression  coefficient  ±  standard  error  0.212  ±  0.059; 
P < 0.001), but decreased as birth order increased (regression coefficient ± 
standard error –0.596 ± 0.230; P = 0.010). (37)
As quoted above in the study done by Juan J. Tarín et al., (37) our study 
also  showed  that  as  the  birth  order  increased  the  probability  of  having 
hypogonadism  decreases.  In  other  words,  the  probability  of  a  man  being 
infertile would be greater if he comes from a small family than if he comes 
from a large family.
           In this study, Arm span, height and weight were significantly higher in 
hypergonadotropic males than hypogonadotropic males. Similar observations 
were found in a recent study done by Lise Aksglaede, Niels E. Skakkebaek (50) 
in  which  they  found  accelerated  growth  in  early  childhood  in  boys  with 
47XXY and 47 XYY karyotype. The abnormal stature of these patients may 
be a result of abnormal gene expression due to the underlying chromosome 
aberration resulting in excessive expression of growth-related genes.
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W          Using  correlation  coefficients,  significant  correlation  was  found 
between various study variables.
      Total testosterone correlated significantly with LH in males. Similar 
observation was found in a study done by PC Sizonenko and  L Paunier, (49) in 
which  they  found major  rise  of  Testosterone,  was  preceded by the  rise  of 
plasma LH and was accompanied by the rise of plasma FSH. 
     Height had a significant correlation with arm span in both males and 
females in our study, which correlates well with the similar observation found 
in  the  study  done  by  Olabinri  B.M,  Olawoye  T  et.al.(51) 
In their African based study, they found that height showed a high positive 
correlation with body’s armspan in males (r = 0.916; P= 0.001), and also, a 
high  positive  significant  correlation  exists  between  height  and  armspan  in 
female children in Ogbomoso, Nigeria .  This finding is in agreement with 
previous study of Torres et al (2003) who found a high significant correlation 
between standing height and armspan in children.  
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SUMMARY
• Hypogonadism is an important problem with which many boys and 
girls  present  to  the  Endocrine  out  patient  department.  They 
experience  significant  emotional  problems  due  to  their  reduced 
secondary sexual characters and delayed puberty. Hence appropriate 
evaluation and reasonable treatment is of paramount importance in 
resuming  fertility  among  them.  This  study  was  conducted  to 
evaluate such patients and to treat them effectively. 
• Most of the individuals presented below the age group of 18 years. 
Very few presented above 18 years. Many of them above 18 years 
were  found to  have  hypergonadotropic  hypogonadism.  Idiopathic 
hypogonadotropic  hypogonadism  was  the  most  common  cause 
among below 18 years.
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• Among the individuals  who presented most  of  them were males, 
only  a  few were  females.  In  males,  Idiopathic  hypogonadotropic 
hypogonadism is the commonest cause, whereas in females many of 
them had Turner’s syndrome. 
• In  our  study,  we  had  few  patients  with  interesting  causes  of 
hypogonadism like kallmann syndrome, vanishing testis syndrome, 
craniopharyngioma and with deficiency of other pituitary hormones 
(hypopituitarism). 
• Birth  order  was  found  to  significantly  influence  the  risk  of 
hypogonadism.  As  the  birth  order  increased  the  risk  reduced 
significantly. 
• Among the anthropometric variables studied, Arm span, height and 
weight in males are found to be significantly higher in patients with 
hypergonadotropic  hypogonadism  (Klinefelter  syndrome),  than 
patients with hypogonadotropic hypogonadism. 
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• A significant  correlation  existed  between  various  study  variables 
especially total testosterone and LH in males, and height and arm 
span in both males and females.
• This  study  shows  the  commonest  cause  of  hypogonadism  is 
Idiopathic Hypogonodotropic Hypogonadism and since it is now a 
treatable  condition,  early  and  correct  diagnosis  is  of  paramount 
importance to the individual, family and society at large. 
CONCLUSIONS:
1. Most  common  age  group  of  presentation  of  hypogonadism patients  is 
below 18 years of age.
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2. Hypogonadism is found to be more common in Males than in females.
3. In  males,  the  most  common  cause  is  Idiopathic  hypogonadotropic 
hypogonadism.
4. A significant association is present between Birth Order and the incidence 
of hypogonadism. Most of the patients are first born.
5. Arm  span,  height  and  weight  varied  significantly  between  Males  of 
hypogonadotropic hypogonadism and hypergonadotropic hypogonadism.
6. A significant  correlation  existed  between  total  testosterone  and  LH in 
males,  whereas arm span and height correlated well  in both males and 
females.
7. This study shows the commonest  cause  of  hypogonadism is  Idiopathic 
Hypogonodotropic  Hypogonadism  and  since  it  is  now  a  treatable 
condition, early and correct diagnosis is of paramount importance to the 
individual, family and society at large. 
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¤ABBREVATIONS AND ACRONYMS
FSH             Follicle Stimulating Hormone
LH               Luteinizing hormone 
DHT            Di-Hydro-Testosterone
GnRH  Gonadotropin Releasing Hormone
hCG Human Chorionic Gonadotropin
rhLH           Recombinant Human Luteinizing hormone
GPR54 G Protein-coupled Receptor
ACTH Adreno-cortico-tropic Hormone
FGFR1 Fibroblast Growth Factor Receptor-1
PROP 1 Prophet of Pit 1
PROK2 Prokineticin 2
AIS Androgen Insensitivity Syndrome
LHR luteinizing Hormone Receptor
FSHR Follicle Stimulating Hormone Receptor
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PROFORMA
PROFORMA FOR HYPOGONADISM
NAME: AGE:         SEX:
ENDOCRINE OP NO:
HISTORY:
H/O of growth abnormality: present or absent
H/O of reduced or delayed development of secondary sexual 
characters: present or absent
H/O abnormal breast enlargement in males: present or absent
H/O of chronic systemic illness like-
H/O recurrent respiratory infection since birth or childhood-present 
or absent
H/O heart disease since birth or childhood- present or absent
H/O persistent diarrhea since childhood-present or absent
H/O delayed milestones: present or absent 
99
H/O reduced intelligence: present or absent
H/O neurological illness since birth or childhood: present or absent
H/O abnormality in sense of smell: present or absent
H/O abnormality of vision: present or absent
Family history:
Pedigree chart:
Menstrual history: attained menarche- yes or no
                               Cycles- regular or not  
CLINICAL EXAMINATION:
Height:           
Weight:           
Arm span:
Head to pubic symphysis (upper segment):
Pubic symphysis to foot (lower segment):  
BUILD:  OBESE OR THIN
GENERAL EXAMINATION:
100
ANEMIA        CLUBBING   CYANOSIS   ICTERUS  
PEDAL EDEMA   LYMPHADENOPATHY
PR:                          BP:
SYSTEMIC EXAMINATION:
CARDIOVASCULAR:
RESPIRATORY:
ABDOMEN:
NERVOUS SYSTEM:
                       SMELL:
                      VISION:
MUSCULOSKELETAL SYSTEM:
SECONDARY SEXUAL CHARACTERS: 
BREASTAND NIPPLES:
SCROTUM:
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TESTIS: RIGHT:                 
                  LEFT:
PENIS:
EXTERNAL GENETALIA - IN FEMALES:
PUBIC HAIR:       
AXILLARY HAIR:
INVESTIGATIONS:
FOLLICLE STIMULATING HARMONE:
LEUTINISING HARMONE:
ESTRADIOL:
FREE TESTOSTERONE:
TOTAL TESTOSTERONE:
TOTAL T4:
FREE T4:
THYROID STIMULATING HARMONE:
SERUM CORTISOL: 8 AM:
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GROWTH HARMONE:
                          BASAL:
       POST CLONIDINE:
PROLACTIN:
ULTRASOUND ABDOMEN AND PELVIS:
OVARIES: RIGHT:    
                     LEFT:
UTERUS:
TESTIS:     RIGHT:                      
                     LEFT:
X RAY CONE VIEW SELLA:
X RAY LEFT HANDS:
MRI SELLA:
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KARYOTYPING:
DIAGNOSIS:
TREATMENT:
104
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